1EUROPEAN HEART RHYTHM ASSOCIATION, HEART RHYTHM SOCIETY, FUSTER V, et al. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Associa- tion Task Force on Practice Guidelines and the European Society of Cardiology, Committee for Practice Guidelines ( Writing Committee to Revise the 2001 Guidelines for the Management of Patients Wilh Atrial Fibrillation) [J].J Am Coll Cardiol, 2006, 48 (4) : 854-906.
2WYSE D G, WALDO A L, DIMARCO J P, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation [ J ]. N Engl J Med, 2002, 347 (23) : 1825-1833.
4DAHLOF B, DEVEREUX R B, KJELDSEN S E, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol [ J ]. Lancet, 2002, 359 (9311): 995-1003.
6VAN DE REE M A, HUISMAN M V, PRINCEN H M, et al. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus [ J ] . Atherosclerosis, 2003, 166 (1) : 129-135.
7CALO L, BIANCONI L, COLIVICCHI F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, con- trolled trial [J]. J Am Coll Cardiol, 2005, 45 (10) : 1723-1728.
8SINGH B N, CONNOLLY S J, CRIJNS H J, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter [J]. N Engl J Med, 2007, 357 (10) : 987-999.
9DORIAN P, PINTER A, MANGAT I, et al. The effect of vemakalant ( RSD1235 ) , an investigational antiarrhythmic agent, on atrial electrophysiology in humans [J]. J Cardiovase Pharmaeol, 2007, 50 (1): 35-40.
10SHIROSHITA-TAKESHITA A, SAKABE M, HAUGAN K, et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs[ J ]. Circulation, 2007, 115 (3): 310-318.
5Fuster V, Ryd6n LE, Cannom DS, et al. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiol- ogy Committee for Practice Guidelines (Writing Commit- tee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) . Circulation, 2006, 114: e257-e354.
6Van Gelder IC, Groenveld HF, Crijns HJ, et al. Leni- ent versus strict rate control in patients with atrial fibril- lation. N Engl J Med, 2010, 362: 1363-1373.
7European Heart Rhythm Association, European Associ- ation for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) . Europace, 2010, 12: 1360-1420.
8Wann LS, Curtis AB, January CT, et al. 2011 ACCF! AHA/HRS focused update on the management of pa- tients with atrial fibrillation (Updating the 2006 Guide- line) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 123: 104- 123.
9Authors/Task Force Members, Camm ALl, Lip GY, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the Euro- pean Heart Rhythm Association. Eur Heart J, 2012, 24.
10Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events ( ACTIVE W) : a random- ised controlled trial. Lancet. 2006. 367, 1903-1912.
